Literature DB >> 17136973

Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions.

Richard Casaburi1.   

Abstract

Constant work rate exercise testing has been used to assess effectiveness of therapeutic interventions in chronic obstructive pulmonary disease. It has been noted to yield larger fractional increases in exercise tolerance than other measures. Reasons for this are rooted in physiological determinants of the time course of pulmonary ventilation. Following exercise onset, ventilation increases in three phases; the slowest phase is seen only at high exercise intensities. In chronic obstructive pulmonary disease exercise proceeds until ventilation reaches a limiting value. Because both ventilatory requirement for exercise and limiting ventilation can be manipulated by several interventions (exercise training, oxygen inhalation, bronchodilator administration), constant work rate tolerance responds to these interventions. The power-duration relationship predicts the effect of the work rate imposed on tolerated duration of a constant work rate test. Arguments are presented that a pre-intervention constant work rate duration of 4-7 minutes is desirable. At present, the recommended strategy to achieve this target duration is to choose a work rate equal to 85% of peak work rate achieved in a constant work rate test. There is clearly insufficient information to reliably determine a minimal clinically important difference for this test. A lower bound of 1.75 minutes is suggested.

Entities:  

Mesh:

Year:  2005        PMID: 17136973     DOI: 10.1081/copd-200050576

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  18 in total

1.  Combination therapy for exercise intolerance in COPD.

Authors:  R Casaburi
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

Review 2.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  Saving Time for Patients with Moderate to Severe COPD: Endurance Test Speed Set Using Usual and Fast Walk Speeds.

Authors:  Thomas E Dolmage; Dmitry Rozenberg; Nina Malek; Rachael A Evans; Roger S Goldstein
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 4.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

5.  Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD.

Authors:  Benoit Borel; Steeve Provencher; Didier Saey; François Maltais
Journal:  Pulm Med       Date:  2013-01-28

Review 6.  Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.

Authors:  Charlotte Suppli Ulrik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-26

7.  Physiological correlates of endurance time variability during constant-workrate cycling exercise in patients with COPD.

Authors:  Isabelle Vivodtzev; Philippe Gagnon; Véronique Pepin; Didier Saey; Louis Laviolette; Cynthia Brouillard; François Maltais
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

Review 8.  Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.

Authors:  Michael W Sims; Reynold A Panettieri
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-16

9.  Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD.

Authors:  Charlotte Suppli Ulrik
Journal:  Open Respir Med J       Date:  2012-12-14

10.  Peak oxygen uptake and breathing pattern in COPD patients--a four-year longitudinal study.

Authors:  Bente Frisk; Jon A Hardie; Birgitte Espehaug; Liv I Strand; Rolf Moe-Nilssen; Tomas M L Eagan; Per S Bakke; Einar Thorsen
Journal:  BMC Pulm Med       Date:  2015-08-19       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.